ADM and pancreatitis: In vivo treatment with the pan-HDAC inhibitors sodium butyrate and trichostatin A (TSA), targeting both class I and class II HDAC subfamilies, reduced ADM, inflammation and fibrosis following induced pancreatitis in rodents [132].